Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2026

Conditions

NSCLC Stage IINSCLC, Stage IIIANSCLC Stage IIIB

Interventions

DRUG

Atezolizumab 1200 mg abs day 1 q22 (iv)

Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)

Trial Locations (1)

RECRUITING

Thoraxklinik Heidelberg gGmbH, Heidelberg

All Listed Sponsors

collaborator

Dietmar Hopp Stiftung

OTHER

lead

University Hospital Heidelberg

OTHER